Moein Moghimi is a British professor and researcher in the fields of nanomedicine, drug delivery and biomaterials. He is currently the professor of Pharmaceutics and Nanomedicine at the School of Pharmacy and the Translational and Clinical Research Institute at Newcastle University. He is also an adjoint professor at the Skaggs School of Pharmacy, University of Colorado Denver. He is known for his fundamental and translational research in nanomedicine and drug delivery, especially in polymeric and nanomaterials' cell and immune safety, and as an inventor of nanosystems for tissue-specific targeting. Moghimi's publications in nanomedicine are widely cited. A study conducted by Stanford University listed Moghimi among the top 0.1% of world's leading scientists across in all fields. He founded the Centre for Pharmaceutical Nanotechnology and Nanotoxicology (CPNN) at University of Copenhagen and was its director until 2016. He co-founded S. M. Discovery Group which develops products based on his inventions. He is currently editor-in-chief of the Journal of Nanotheranostics.
Early life and education Moghimi completed his secondary education at D'Overbroeck's College in Oxford, United Kingdom. He pursued a bachelor's degree in biochemistry at the University of Manchester and graduated with honors in 1985. He completed his PhD in liposome immunobiology/biochemistry in 1989 at the Biochemistry Department of the Charing Cross Hospital Medical School at Imperial College London (then University of London) under the mentorship of Harish M. Patel. He then joined Stanley Stewart Davis' laboratory at the Department of Pharmaceutical Sciences, University of Nottingham for postdoctoral training in advanced drug delivery system engineering. Later he became a University Research Fellow at University of Nottingham.
Academic career Moghimi was the senior lecturer of Biopharmacy and Molecular Pharmaceutics at the School of Pharmacy, University of Brighton from 1998 until 2008. From 2008 until 2010, he was honorary professor of nanomedicine at the Multidisciplinary Research Center, Shantou University. He was also a full affiliate professor at the Methodist Research Institute, Houston Methodist Hospital systems in Texas between 2013 and 2017. From 2008 until 2016, he was professor of nanomedicine in the department of pharmacy and professor of pharmaceutical nanotechnology at the Nanoscience Center, as well as the founder and director of the Centre for Pharmaceutical Nanotechnology and Nanotoxiocology at the University of Copenhagen. Prior to 2017, Moghimi was professor and chair in pharmaceutics at the Durham University School of Medicine, Pharmacy and Health. Since 2017, he has been professor of Pharmaceutics and Nanomedicine at the School of Pharmacy and Translational and Clinical Research Institute, both part of Newcastle University. He is adjoint professor at the department of pharmaceutical sciences at Skaggs School of Pharmacy, University of Colorado Denver Medical Center.
Editorial activities Moghimi is Editor-in-Chief of the Journal of Nanotheranostics and Drug Delivery. He is associate editor of Precision Nanomedicine, Molecular Therapy, and serves on the editorial boards of journals such as Advanced Drug Delivery Reviews, Journal of Controlled Release, and Nanomedicine-UK.
… excerpt ends here. Continue reading the full article.
